U.S. Liquid Biopsy Market Size & Outlook, 2024-2030
Related Markets
U.S. liquid biopsy market highlights
- The U.S. liquid biopsy market generated a revenue of USD 4,980.2 million in 2024 and is expected to reach USD 9,561.4 million by 2030.
- The U.S. market is expected to grow at a CAGR of 11.4% from 2025 to 2030.
- In terms of segment, blood sample based was the largest revenue generating type in 2024.
- Blood Sample Based is the most lucrative type segment registering the fastest growth during the forecast period.
Liquid biopsy market data book summary
| Market revenue in 2024 | USD 4,980.2 million |
| Market revenue in 2030 | USD 9,561.4 million |
| Growth rate | 11.4% (CAGR from 2025 to 2030) |
| Largest segment | Blood sample based |
| Fastest growing segment | Blood Sample Based |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample Based |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, U.S. accounted for 42.0% of the global liquid biopsy market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. liquid biopsy market is projected to lead the regional market in terms of revenue in 2030.
- Mexico is the fastest growing regional market in North America and is projected to reach USD 132.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample based was the largest segment with a revenue share of 81.31% in 2024. Horizon Databook has segmented the U.S. liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2018 to 2030.
The U.S. accounted for the major revenue share of the liquid biopsy market in 2023. Rapid technological advancements, recent FDA approvals for liquid biopsy tests, and intense competition between companies are expected to boost market growth over the forecast period.
According to the American Cancer Society, in 2021, 235,760 people are estimated to be diagnosed with non-small cell lung cancer, the most common form of lung cancer in the U.S. Overall, around 1 in 17 men and 1 in 15 women are at risk of developing lung cancer in their lifetime.
Roche's cobas liquid biopsy test was approved for use in patients with non-small cell lung cancer to identify specific genetic mutations in the tumor. Moreover, the launch of novel diagnostics solutions is expected to propel the market further.
Reasons to subscribe to U.S. liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. liquid biopsy market , including forecasts for subscribers. This country databook contains high-level insights into U.S. liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. liquid biopsy market size, by type, 2018-2030 (US$M)
U.S. Liquid Biopsy Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
